Market Considerations in Europe Outlook - Featured Research on Advanced Cell Technology, Inc. and Cell Therapeutics, Inc.
November 10, 2011 09:00 ET
Market Considerations in Europe Outlook - Featured Research on Advanced Cell Technology, Inc. and Cell Therapeutics, Inc.
NEW YORK, NY--(Marketwire - Nov 10, 2011) - Today, [ www.BollingerReport.com ] introduced featured coverage of Advanced Cell Technology, Inc. (
With the European Financial Stability Facility set to increase to $1.4 trillion, it marks a significant move forward to strengthen the safety net in place for Europe's most troubled countries. Private bondholders of Greek debt are settling at a 50% haircut as another $180 billion in fresh aid is set to arrive, enabling banks to recapitalize at a healthy 9% reserve. Overall, these measures will bring Greece's debt burden down to 120% of GDP by 2020. An important consideration is political commitment to this road map. Currently the global community appears to be on point with ECB's initiative, an outlook that should be sufficient to support markets around current levels.
Bollinger Report screened and selected Advanced Cell Technology, Inc. for its current position within the industry. Advanced Cell Technology, Inc. is a biotechnology company focused on developing and commercializing human embryonic and adult stem cell technology in the emerging field of regenerative medicine. A copy of this report featuring Advanced Cell Technology, Inc. (
Bollinger Report is featuring Cell Therapeutics, Inc. for its changing role within the healthcare industry. Cell Therapeutics, Inc. (CTI) develops, acquires and commercializes treatments for cancer. CTI is focused on the development, acquisition and commercialization of treatments for cancer. It focuses on building a biopharmaceutical company with a diversified portfolio of oncology drugs. To download researches and analysis on Cell Therapeutics, Inc. (
About Bollinger Report
Bollinger Report has come to be known among its peers as a trusted source of information for both investors and technical traders. Our online content is continually updated, bringing fresh new researches and analyses to the investment community.